CN115232154A - 杂环类衍生物抑制剂、其制备方法和应用 - Google Patents

杂环类衍生物抑制剂、其制备方法和应用 Download PDF

Info

Publication number
CN115232154A
CN115232154A CN202210431665.2A CN202210431665A CN115232154A CN 115232154 A CN115232154 A CN 115232154A CN 202210431665 A CN202210431665 A CN 202210431665A CN 115232154 A CN115232154 A CN 115232154A
Authority
CN
China
Prior art keywords
alkyl
amino
cycloalkyl
alkoxy
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210431665.2A
Other languages
English (en)
Chinese (zh)
Inventor
高鹏
曾蜜
王少宝
俞文胜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hansoh Biomedical Co Ltd filed Critical Shanghai Hansoh Biomedical Co Ltd
Publication of CN115232154A publication Critical patent/CN115232154A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202210431665.2A 2021-04-23 2022-04-22 杂环类衍生物抑制剂、其制备方法和应用 Pending CN115232154A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
CN2021104435820 2021-04-23
CN202110443582 2021-04-23
CN202110653169 2021-06-11
CN2021106531697 2021-06-11
CN2021108083163 2021-07-16
CN202110808316 2021-07-16
CN2021109266763 2021-08-12
CN202110926676 2021-08-12
CN202210072358 2022-01-21
CN202210072358X 2022-01-21

Publications (1)

Publication Number Publication Date
CN115232154A true CN115232154A (zh) 2022-10-25

Family

ID=83668197

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210431665.2A Pending CN115232154A (zh) 2021-04-23 2022-04-22 杂环类衍生物抑制剂、其制备方法和应用
CN202280007892.0A Pending CN116601148A (zh) 2021-04-23 2022-04-22 杂环类衍生物抑制剂、其制备方法和应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280007892.0A Pending CN116601148A (zh) 2021-04-23 2022-04-22 杂环类衍生物抑制剂、其制备方法和应用

Country Status (12)

Country Link
US (1) US20240228490A1 (https=)
EP (1) EP4328225A4 (https=)
JP (1) JP2024514338A (https=)
KR (1) KR20240005756A (https=)
CN (2) CN115232154A (https=)
AU (1) AU2022261029A1 (https=)
BR (1) BR112023019797A2 (https=)
CA (1) CA3215823A1 (https=)
IL (1) IL307824A (https=)
MX (1) MX2023012054A (https=)
TW (1) TW202309026A (https=)
WO (1) WO2022223025A1 (https=)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116375700A (zh) * 2023-01-10 2023-07-04 中国科学院成都生物研究所 一种4-氮杂吲哚啉类化合物及其合成方法与应用
WO2023138541A1 (zh) * 2022-01-20 2023-07-27 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
WO2023146957A1 (en) * 2022-01-27 2023-08-03 Xinthera, Inc. Parp1 inhibitors and uses thereof
CN116867784A (zh) * 2021-04-23 2023-10-10 成都百裕制药股份有限公司 吡啶衍生物及其在医药上的应用
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
WO2024041605A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024046420A1 (zh) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 稠合二环类化合物、其制备方法及其在医药上的应用
WO2024046366A1 (zh) * 2022-09-01 2024-03-07 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024067691A1 (zh) * 2022-09-30 2024-04-04 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
CN117903159A (zh) * 2022-12-30 2024-04-19 成都硕德药业有限公司 一种内酰胺类衍生物、其制备方法及用途
WO2024083201A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 并杂环类化合物及其用途
WO2024082654A1 (zh) * 2022-10-20 2024-04-25 上海海和药物研究开发股份有限公司 具有parp1抑制活性的化合物及其用途
WO2024093956A1 (zh) * 2022-11-02 2024-05-10 山东轩竹医药科技有限公司 多环类聚(adp核糖)聚合酶选择性抑制剂
US12054479B1 (en) 2022-03-14 2024-08-06 Slap Pharmaceuticals Llc Multicyclic compounds
WO2024179547A1 (en) * 2023-03-01 2024-09-06 Impact Therapeutics (Shanghai) , Inc. Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
WO2024188265A1 (zh) * 2023-03-13 2024-09-19 江苏豪森药业集团有限公司 哌啶烯类化合物在制备治疗癌症的药物中的应用
CN119039301A (zh) * 2024-10-31 2024-11-29 江苏豪森药业集团有限公司 一种含氮杂环的多环化合物晶型ⅰ的制备方法
WO2025026195A1 (zh) * 2023-07-28 2025-02-06 广东东阳光药业股份有限公司 取代的含氮双环化合物及其用途
WO2025036290A1 (zh) * 2023-08-11 2025-02-20 上海海和药物研究开发股份有限公司 稠合三环类化合物、其药物组合物和用途
WO2025035449A1 (en) * 2023-08-17 2025-02-20 Dic Corporation Compound and liquid crystal composition, liquid crystal display device, sensor, liquid crystal lens, optical communication device, and antenna using the compound
WO2025168048A1 (zh) * 2024-02-08 2025-08-14 上海璎黎药业有限公司 一种三键结构化合物、其药物组合物及其应用
EP4450498A4 (en) * 2021-12-17 2025-12-03 Keythera Suzhou Bio Pharmaceuticals Co Ltd PARP INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING IT AND ITS USE

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309025A (zh) 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
US20230159525A1 (en) 2021-10-01 2023-05-25 Xinthera, Inc. Azetidine and pyrrolidine parp1 inhibitors and uses thereof
JP7762306B2 (ja) * 2021-11-19 2025-10-29 康百達（四川）生物医薬科技有限公司 選択的ｐａｒｐ１阻害剤およびその用途
CN116143776A (zh) * 2021-11-22 2023-05-23 南京圣和药业股份有限公司 Parp1抑制剂及其应用
AU2023209820B2 (en) 2022-01-21 2024-10-10 Xinthera, Inc. Parp1 inhibitors and uses thereof
FI4497438T3 (fi) 2022-04-28 2025-10-20 Xinthera Inc Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja
WO2023207284A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
CN115919859B (zh) * 2022-07-14 2024-01-05 四川海思科制药有限公司 一种杂芳基衍生物的药物组合物及其在医药上的应用
US20240132449A1 (en) * 2022-08-30 2024-04-25 1Cbio, Inc. Heterocyclic compounds and methods of use thereof
TW202415658A (zh) * 2022-09-30 2024-04-16 大陸商中國醫藥研究開發中心有限公司 含氮雜環類化合物及其醫藥用途
WO2024083218A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 取代四氢吡啶类化合物及其用途
EP4615581A2 (en) * 2022-11-09 2025-09-17 Laekna Pharmaceutical Ningbo Co., Ltd. Fused multicyclic compounds and their use as parp1 inhibitors
EP4669633A1 (en) * 2023-02-21 2025-12-31 1Cbio, Inc. HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THEM
WO2024178125A1 (en) * 2023-02-21 2024-08-29 1Cbio, Inc. Heterocyclic compounds and methods of use thereof
WO2025103407A1 (zh) * 2023-11-16 2025-05-22 江苏豪森药业集团有限公司 抗体药物偶联物和多腺苷二磷酸核糖聚合酶抑制剂的联合应用
WO2025265123A1 (en) * 2024-06-21 2025-12-26 Protheragen Inc. Parp1 inhibitors for the treatment of diseases
WO2026002281A1 (zh) * 2024-06-28 2026-01-02 上海翰森生物医药科技有限公司 哌啶烯类化合物联合用药在制备治疗癌症的药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1190466B (de) * 1961-11-07 1965-04-08 Cassella Farbwerke Mainkur Ag Verfahren zur Herstellung von Piperazinderivaten
HUP9903758A3 (en) * 1996-05-29 2000-07-28 Warner Lambert Co Benzoxazinone dopamine d4 receptor antagonists and pharmaceutical compositions containing the same
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
EA010592B1 (ru) * 2003-12-10 2008-10-30 Янссен Фармацевтика Н.В. 6-замещённые циклогексилалкил 2-замещённые хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(adp-рибоза)полимеразы
RU2007101544A (ru) * 2004-06-17 2008-08-10 Уайт (Us) Антагонисты рецепторов высвобождающего гонадотропин гормона
US8404713B2 (en) * 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
WO2010111626A2 (en) * 2009-03-27 2010-09-30 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
EP3804336A4 (en) * 2018-07-11 2021-08-11 Huawei Technologies Co., Ltd. FILTERING PROCESS AND APPARATUS DEPENDING ON THE ASPECT RATIO FOR INTRA-PREDICTION
MX2022000711A (es) * 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116867784A (zh) * 2021-04-23 2023-10-10 成都百裕制药股份有限公司 吡啶衍生物及其在医药上的应用
CN116867783A (zh) * 2021-04-23 2023-10-10 成都百裕制药股份有限公司 吡啶衍生物及其在医药上的应用
EP4450498A4 (en) * 2021-12-17 2025-12-03 Keythera Suzhou Bio Pharmaceuticals Co Ltd PARP INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING IT AND ITS USE
CN118434725B (zh) * 2022-01-20 2026-01-02 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
WO2023138541A1 (zh) * 2022-01-20 2023-07-27 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
CN118434725A (zh) * 2022-01-20 2024-08-02 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
WO2023146957A1 (en) * 2022-01-27 2023-08-03 Xinthera, Inc. Parp1 inhibitors and uses thereof
US12054479B1 (en) 2022-03-14 2024-08-06 Slap Pharmaceuticals Llc Multicyclic compounds
WO2024041605A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
WO2024046420A1 (zh) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 稠合二环类化合物、其制备方法及其在医药上的应用
CN119365468A (zh) * 2022-08-31 2025-01-24 江苏恒瑞医药股份有限公司 稠合二环类化合物、其制备方法及其在医药上的应用
WO2024046366A1 (zh) * 2022-09-01 2024-03-07 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024067691A1 (zh) * 2022-09-30 2024-04-04 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
WO2024082654A1 (zh) * 2022-10-20 2024-04-25 上海海和药物研究开发股份有限公司 具有parp1抑制活性的化合物及其用途
WO2024083201A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 并杂环类化合物及其用途
WO2024093956A1 (zh) * 2022-11-02 2024-05-10 山东轩竹医药科技有限公司 多环类聚(adp核糖)聚合酶选择性抑制剂
CN117903159A (zh) * 2022-12-30 2024-04-19 成都硕德药业有限公司 一种内酰胺类衍生物、其制备方法及用途
CN116375700A (zh) * 2023-01-10 2023-07-04 中国科学院成都生物研究所 一种4-氮杂吲哚啉类化合物及其合成方法与应用
WO2024179547A1 (en) * 2023-03-01 2024-09-06 Impact Therapeutics (Shanghai) , Inc. Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
WO2024188265A1 (zh) * 2023-03-13 2024-09-19 江苏豪森药业集团有限公司 哌啶烯类化合物在制备治疗癌症的药物中的应用
WO2025026195A1 (zh) * 2023-07-28 2025-02-06 广东东阳光药业股份有限公司 取代的含氮双环化合物及其用途
WO2025036290A1 (zh) * 2023-08-11 2025-02-20 上海海和药物研究开发股份有限公司 稠合三环类化合物、其药物组合物和用途
WO2025035449A1 (en) * 2023-08-17 2025-02-20 Dic Corporation Compound and liquid crystal composition, liquid crystal display device, sensor, liquid crystal lens, optical communication device, and antenna using the compound
WO2025168048A1 (zh) * 2024-02-08 2025-08-14 上海璎黎药业有限公司 一种三键结构化合物、其药物组合物及其应用
CN119039301A (zh) * 2024-10-31 2024-11-29 江苏豪森药业集团有限公司 一种含氮杂环的多环化合物晶型ⅰ的制备方法

Also Published As

Publication number Publication date
JP2024514338A (ja) 2024-04-01
TW202309026A (zh) 2023-03-01
US20240228490A1 (en) 2024-07-11
WO2022223025A1 (zh) 2022-10-27
CN116601148A (zh) 2023-08-15
CA3215823A1 (en) 2022-10-27
AU2022261029A1 (en) 2023-10-19
IL307824A (en) 2023-12-01
MX2023012054A (es) 2023-10-23
BR112023019797A2 (pt) 2023-11-07
KR20240005756A (ko) 2024-01-12
EP4328225A4 (en) 2025-03-26
EP4328225A1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
CN115232154A (zh) 杂环类衍生物抑制剂、其制备方法和应用
CN112552294B (zh) 含哌嗪杂环类衍生物抑制剂、其制备方法和应用
TWI527800B (zh) 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用
WO2020073945A1 (zh) 双环类衍生物抑制剂、其制备方法和应用
TW202108582A (zh) 含二並環類衍生物抑制劑、其製備方法和應用
TW201518278A (zh) 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
WO2018137639A1 (zh) 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
CN116891456A (zh) 杂环类衍生物抑制剂、其制备方法和应用
CN109745321B (zh) 包含fgfr4抑制剂的药物组合物
CN106187915A (zh) 具有alk与egfr双重活性的抑制剂及其制备方法和应用
JP2022534063A (ja) インドール誘導体含有阻害剤、そのための調製方法及びその用途
JP2023509155A (ja) ビフェニル系誘導体阻害剤、その調製方法及び使用
KR20250073643A (ko) Parg 억제 화합물
JP2021536436A (ja) キノリン誘導体から調製される新規な阻害剤
WO2020020385A1 (zh) 含三并环类衍生物抑制剂、其制备方法和应用
WO2024109885A1 (zh) 吡啶多环类化合物抑制剂、及其制备方法和应用
TW201917129A (zh) 含吡唑基的三并環類衍生物、其製備方法和應用
EP4606802A1 (en) Salt and crystal form of heterocyclic derivative inhibitor, and preparation method therefor and use thereof
WO2022100738A1 (zh) 含二并环类衍生物抑制剂自由碱的晶型及其制备方法和应用
WO2021197250A1 (zh) 作为转染期间重排激酶抑制剂的新的化合物
TW202416971A (zh) 甲醯胺取代的雜三環類衍生物、其製備方法及其應用
CN114502556B (zh) 一种联苯基氟代双键衍生物及其制备方法和在药学上的应用
WO2023134764A1 (zh) 含吡啶多环类衍生物、其制备方法和应用
WO2022042612A1 (zh) 二氢吡咯并[2,3-d]哒嗪-7-酮衍生物，其制备方法和应用
JP2022551180A (ja) イソクエン酸デヒドロゲナーゼ（ｉｄｈ）阻害剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination